Harout Semerjian

Harout Semerjian

-President and Chief Executive OfficeratCrescent Biopharma· In proxies 2022–2023

Pay in FY2023+67% from the year before · Crescent Biopharma stock -22.1% the same year

Harout Semerjian was paid $2.4M in FY2023 (Dec), up 67%. Crescent Biopharma stock fell 22.1% that year.

Pay$100 in the stock at the end of FY21 → $164
Pay is from the Summary Compensation Table of each Crescent Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Crescent BiopharmaPublic company · 4 yr
    • -President and Chief Executive Officer2022 – Present · 4 yrStock in role -91%
  2. Biotechnology Innovation OrganizationPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?